Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
The latest update is out from Assertio Therapeutics ( (ASRT) ).
On November 17, 2025, Brendan P. O’Grady, former CEO of Assertio Holdings, Inc., executed a waiver and release agreement, leading to his resignation from the company’s Board of Directors. This move marks a significant leadership change within the company, potentially impacting its strategic direction and stakeholder interests.
The most recent analyst rating on (ASRT) stock is a Hold with a $0.50 price target. To see the full list of analyst forecasts on Assertio Therapeutics stock, see the ASRT Stock Forecast page.
Spark’s Take on ASRT Stock
According to Spark, TipRanks’ AI Analyst, ASRT is a Neutral.
Assertio Therapeutics faces significant financial challenges, with negative profitability and cash flow issues being the most impactful factors. While the earnings call provided some positive insights into sales growth and strategic advancements, the overall financial health and valuation concerns weigh heavily on the stock’s attractiveness. Technical indicators also suggest a bearish outlook, further contributing to the low overall score.
To see Spark’s full report on ASRT stock, click here.
More about Assertio Therapeutics
Average Trading Volume: 394,811
Technical Sentiment Signal: Strong Sell
Current Market Cap: $72.09M
For a thorough assessment of ASRT stock, go to TipRanks’ Stock Analysis page.